Arca Biopharma Announces Gencaro Atrial Fibrillation Clinical Data Selected for Presentation at HFSA 2019 Scientific Meeting
11 sept. 2019 08h30 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., Sept. 11, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
Biomerica Announces Fiscal Year End 2019 Financial Results
30 août 2019 08h30 HE
|
Biomerica, Inc.
IRVINE, Calif., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today reported net sales for the fiscal year 2019 were $5,200,682...
Axiom Real-Time Metrics is a Proud Supporter of 'Women Breaking the Barriers of Science & Their Male Champions', a BVS La Jolla Biotech Community Event
29 août 2019 12h08 HE
|
Axiom Real-Time Metrics Inc
TORONTO, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics (“Axiom”), premier provider of unified eClinical solutions and services is supporting and exhibiting at an event today showcasing...
DrugCendR Inc. Announces the Appointment of Dr. Daniel Von Hoff as Clinical Advisor
20 août 2019 13h17 HE
|
DrugCendR Inc.
LA JOLLA, Calif., Aug. 20, 2019 (GLOBE NEWSWIRE) -- DrugCendR, Inc., a clinical-stage biotech company developing next generation therapies for the treatment of solid tumors, today announced that Dr....
BioAegis Therapeutics Reports Favorable Safety and Pharmacokinetic Results in its Phase 1b/2a Dose-Escalation Study of Recombinant Human Plasma Gelsolin with Highest Doses Ever Administered to Patients
07 août 2019 10h00 HE
|
BioAegis Therapeutics
MORRISTOWN, N.J., Aug. 07, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc. announced the major findings from its Phase 1b/2a study of Recombinant Human Plasma Gelsolin for patients requiring...
Zynerba Pharmaceuticals Announces Publication of Zygel™ (ZYN002) 12-week Open Label Fragile X Syndrome Data in the Journal of Neurodevelopmental Disorders
06 août 2019 08h00 HE
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare...
Rafael Pharmaceuticals Launches Clinical Trial Web Portal “Rafael Trial Connect”
05 août 2019 09h00 HE
|
Rafael Pharmaceutical Inc.
Newark, NJ, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today the...
ARCA biopharma Announces Second Quarter 2019 Financial Results and Provides Corporate Update
01 août 2019 16h30 HE
|
ARCA biopharma, Inc.
FDA SPA Agreement for Phase 3 atrial fibrillation trial (PRECISION-AF) amended to expand patient population to include heart failure patients with preserved ejection fraction (HFpEF)PRECISION-AF...
Rafael Pharmaceuticals Announces Expansion into Austria, South Korea and Spain of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
01 août 2019 10h15 HE
|
Rafael Pharmaceutical Inc.
Cranbury, NJ, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals Announces Expansion into Austria, South Korea and Spain of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in...
AZTherapies Completes Enrollment in COGNITE Pivotal Phase 3 Trial of ALZT-OP1 for the Treatment of Early Alzheimer’s Disease
01 août 2019 08h32 HE
|
AZTherapies, Inc.
First-in-class candidate targets microglia to slow or halt neuroinflammation and disease progression ALZT-OP1 trial being conducted under an SPA with expected completion in late 2020 BOSTON, Aug. ...